Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Low Frequency of EGFR Mutations in Pleural Mesothelioma Patients, Cologne, Germany.

Schildgen V, Pabst O, Tillmann RL, Lüsebrink J, Schildgen O, Ludwig C, Brockmann M, Stoelben E.

Diagn Mol Pathol. 2014 Feb 24. [Epub ahead of print]

PMID:
24569782
2.

Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany.

Schildgen V, Pabst O, Tillmann RL, Lüsebrink J, Schildgen O, Ludwig C, Brockmann M, Stoelben E.

Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):118-25. doi: 10.1097/PDM.0b013e3182a3645e.

PMID:
25679064
3.

Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.

Enomoto Y, Kasai T, Takeda M, Takano M, Morita K, Kadota E, Iizuka N, Maruyama H, Haratake J, Kojima Y, Ikeda N, Inatsugi N, Nonomura A.

J Clin Pathol. 2012 Jun;65(6):522-7. doi: 10.1136/jclinpath-2011-200631. Epub 2012 Mar 12.

PMID:
22412050
4.

Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.

Buttitta F, Felicioni L, Del Grammastro M, Filice G, Di Lorito A, Malatesta S, Viola P, Centi I, D'Antuono T, Zappacosta R, Rosini S, Cuccurullo F, Marchetti A.

Clin Cancer Res. 2013 Feb 1;19(3):691-8. doi: 10.1158/1078-0432.CCR-12-1958. Epub 2012 Dec 14.

5.

Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.

Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.

J Cancer Res Clin Oncol. 2008 Oct;134(10):1105-11. doi: 10.1007/s00432-008-0384-4. Epub 2008 Apr 8.

PMID:
18392851
6.

Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.

Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, Nath SK, Loggie BW.

World J Surg Oncol. 2010 Oct 13;8:88. doi: 10.1186/1477-7819-8-88.

7.

Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.

Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW.

Ann Surg Oncol. 2009 Jan;16(1):152-8. doi: 10.1245/s10434-008-0206-6. Epub 2008 Nov 8.

PMID:
18998063
8.

[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].

Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ.

Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):119-23. Chinese.

PMID:
17645848
9.

Second generation sequencing of the mesothelioma tumor genome.

Bueno R, De Rienzo A, Dong L, Gordon GJ, Hercus CF, Richards WG, Jensen RV, Anwar A, Maulik G, Chirieac LR, Ho KF, Taillon BE, Turcotte CL, Hercus RG, Gullans SR, Sugarbaker DJ.

PLoS One. 2010 May 13;5(5):e10612. doi: 10.1371/journal.pone.0010612.

10.
11.

Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.

Favoni RE, Pattarozzi A, Lo Casto M, Barbieri F, Gatti M, Paleari L, Bajetto A, Porcile C, Gaudino G, Mutti L, Corte G, Florio T.

Curr Cancer Drug Targets. 2010 Mar;10(2):176-91.

PMID:
20088784
12.

[Screening for EGFR mutations in lung cancer by a novel real-time PCR with double-loop probe and Sanger DNA sequencing].

Zhang HP, Ruan L, Zheng LM, Bai DY, Zhang HF, Liao YQ, Ding Y.

Zhonghua Zhong Liu Za Zhi. 2013 Jan;35(1):28-32. doi: 10.3760/cma.j.issn.0253-3766.2013.01.006. Chinese.

PMID:
23648296
13.

[Analysis of EGFR mutations in 176 cases of non-small cell lung cancer].

Dong QG, Han BH, Huang JS, Yang LM, Huang J, Zhao CY, Lu LQ.

Zhonghua Zhong Liu Za Zhi. 2006 Sep;28(9):686-90. Chinese.

PMID:
17274376
14.

Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers.

Trupiano JK, Geisinger KR, Willingham MC, Manders P, Zbieranski N, Case D, Levine EA.

Mod Pathol. 2004 Apr;17(4):476-81.

15.

p53 and Kirsten-ras mutations in human mesothelioma cell lines.

Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Gerwin BI, et al.

Cancer Res. 1992 May 1;52(9):2610-5.

16.

EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.

Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S, Roncalli M.

Lung Cancer. 2006 Feb;51(2):207-15. Epub 2005 Dec 27.

PMID:
16384623
17.

Mutations of the 5 alpha-reductase type 2 gene in eight Mexican patients from six different pedigrees with 5 alpha-reductase-2 deficiency.

Canto P, Vilchis F, Chávez B, Mutchinick O, Imperato-McGinley J, Pérez-Palacios G, Ulloa-Aguirre A, Méndez JP.

Clin Endocrinol (Oxf). 1997 Feb;46(2):155-60.

PMID:
9135696
18.

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL; Cancer and Leukemia Group B (CALGB 30101)..

Clin Cancer Res. 2005 Mar 15;11(6):2300-4.

19.

Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.

Centeno I, Blay P, Santamaría I, Astudillo A, Pitiot AS, Osorio FG, González-Arriaga P, Iglesias F, Menéndez P, Tardón A, Freije JM, Balbín M.

BMC Cancer. 2011 May 16;11:172. doi: 10.1186/1471-2407-11-172.

20.

Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.

Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, Abdel-Hamid A, Eldin NA, Mokhtar N.

Lung Cancer. 2010 Oct;70(1):43-50. doi: 10.1016/j.lungcan.2010.01.002. Epub 2010 Mar 27.

PMID:
20347505

Supplemental Content

Support Center